膀胱腔内热化疗联合应用预防肿瘤复发疗效观察  

Clinical results of intravesical hyperthmia combined with intravesical chemotherapy for the prevention of recurrence of bladder neopalasms

作　　者：张卫星[1] 陈尧康[1] 虞利民[1] 何小祥[1] 高锦春[1] 

机构地区：[1]绍兴第二医院泌尿外科,浙江绍兴312000

出　　处：《临床泌尿外科杂志》2006年第5期355-357,共3页Journal of Clinical Urology

摘　　要：目的:降低膀胱移行细胞癌术后复发率,评价热、化疗联合应用的疗效及安全性。方法:对40例膀胱移行细胞癌术后患者,在膀胱腔内局部恒温热盐水持续灌注,每次10000ml,每日一次,10次为一疗程。同时吡柔比星20mg/40ml膀胱腔内灌注,每周一次,连续8次,总用量为160mg。结果:40例患者均获随访。随访时间9～52个月,除1例术后10个月、1例术后30个月复发外,余38例均未见肿瘤复发及转移。复发率为5%。结论:膀胱腔内热化疗联合应用预防移行细胞癌术后复发效果满意,安全性好。Objective：To evaluate the efficacy and safety of intravesical hyperthmia combined with intravesical pirarubicin to prevent recurrence of transitional cell carcinoma of bladder after surgery. Methods： Fourty cases of bladder cancer who underwent surgical management received intravesical constant temperature sodium chloride solusion 1000 ml every time, 10 times as one treatment period. Then pirarubicin was given for intravesical instillation every week, for totally 8 weeks. Results： All 40 cases were followed up for 9 months to 52 months. Two cases got recurrence within 3 year. The recurrence rate was 5%. No obvious side effect was found in all cases. Conclusions： Intravesical hyperthmia combined with intravesical instillation of pirarubicin is effective for preventing the recurrence of transitional cell carcinoma of bladder after surgical management with few side effects.

关 键 词：膀胱癌 腔内热疗 腔内化疗 复发率 联合应用 

分 类 号：R737.14[医药卫生—肿瘤]